- Cumplido Mayoral, Irene
- García Prat, Marina
- Operto, Grégory
- Falcón Falcón, Carles
- Shekari, Mahnaz
- Cacciaglia, Raffaele
- Milà Alomà, Marta
- Lorenzini, Luigi
- Ingala, Silvia
- Vilaplana Besler, Verónica
Brain-age can be inferred from structural neuroimaging and compared to chronological age (brain-age delta) as a marker of biological brain aging. Accelerated aging has been found in neurodegenerative disorders like Alzheimer's disease (AD), but its validation against markers of neurodegeneration and AD is lacking. Here, imaging-derived measures from the UK Biobank dataset (N=22,661) were used to predict brain-age in 2,314 cognitively unimpaired (CU) individuals at higher risk of AD and mild cognitive impaired (MCI) patients from four independent cohorts with available biomarker data: ALFA+, ADNI, EPAD and OASIS. Brain-age delta was associated with abnormal amyloid-b, more advanced stages (AT) of AD pathology and APOE-e4 status. Brain-age delta was positively associated with plasma neurofilament light, a marker of neurodegeneration, and sex differences in the brain effects of this marker were found. These results validate brain-age delta as a non-invasive marker of biological brain aging in non-demented individuals with abnormal levels of biomarkers of AD and axonal injury., Marc Suárez-Calvet: Horizon 2020 - Research and Innovation Framework Programme 948677, Instituto de Salud Carlos III PI19/00155, La Caixa Foundation 100010434, Horizon 2020 - Research and Innovation Framework Programme 847648 / Juan Domingo Gispert: EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD 115952 / Marc Suárez-Calvet: La Caixa Foundation 100010434; LCF/PR/ GN17/50300004 / Irene Cumplido-Mayoral: TriBEKa Imaging Platform project TriBEKa-17-519007, Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government 2017-SGR-892 / Juan Domingo Gispert: EIT Digital Grant 2021, Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI) MCIN/AEI /10.13039/501100011033 RTI2018-102261, cofunded by the European Regional Development Fund (FEDER) / Marc Suárez-Calvet: NIHR biomedical research center at UCLH Frederik Barkhof Instituto de Salud Carlos III PI22/00456 / Raffaele Cacciaglia: Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI) MCIN/ AEI/10.13039/501100011033 PID2021-125433OA-100 / Verónica Vilaplana: Spanish Research Agency (AEI) PID2020-116907RB-I00 of the call MCIN/ AEI /10.13039/501100011033, Peer Reviewed, Article signat per 27 autors/es:
Irene Cumplido-Mayoral, Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain;
Marina García-Prat, Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain;
Grégory Operto, Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain;
Carles Falcon, Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain;
Mahnaz Shekari, Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain;
Raffaele Cacciaglia, Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain;
Marta Milà-Alomà, Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain;
Luigi Lorenzini, Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, Netherlands;
Silvia Ingala, Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, Netherlands;
Alle Meije Wink, Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, Netherlands;
Henk JMM Mutsaerts, Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, Netherlands;
Carolina Minguillón, Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain;
Karine Fauria, Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain;
José Luis Molinuevo, Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain;
Sven Haller, CIRD Centre d'Imagerie Rive Droite, Geneva, Switzerland;
Gael Chetelat, Normandie Univ, UNICAEN, INSERM, U1237, Caen, France;
Adam Waldman, Centre for Dementia Prevention, University of Edinburgh, Edinburgh, United Kingdom;
Adam J Schwarz, Takeda Pharmaceutical Company Ltd, Cambridge, United States;
Frederik Barkhof, Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, Netherlands;
Ivonne Suridjan, Roche Diagnostics International Ltd, Rotkreuz, Switzerland;
Gwendlyn Kollmorgen, Roche Diagnostics GmbH, Penzberg, Germany;
Anna Bayfield, Roche Diagnostics GmbH, Penzberg, Germany;
Henrik Zetterberg, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden;
Kaj Blennow, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden;
Marc Suárez-Calvet, Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain;
Verónica Vilaplana, Department of Signal Theory and Communications, Universitat Politècnica de Catalunya, Barcelona, Spain;
Juan Domingo Gispert López, Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain, Postprint (published version)